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Abstract: Epigenetic editing, an emerging technique used for the modulation of gene
expression in mammalian cells, is a promising strategy to correct disease-related gene expression.
Although epigenetic reprogramming results in sustained transcriptional modulation in several in vivo
models, further studies are needed to develop this approach into a straightforward technology for
effective and specific interventions. Important goals of current research efforts are understanding
the context-dependency of successful epigenetic editing and finding the most effective epigenetic
effector(s) for specific tasks. Here we tested whether the fibrosis- and cancer-associated PLOD2 gene
can be repressed by the DNA methyltransferase M.SssI, or by the non-catalytic Krüppel associated
box (KRAB) repressor directed to the PLOD2 promoter via zinc finger- or CRISPR-dCas9-mediated
targeting. M.SssI fusions induced de novo DNA methylation, changed histone modifications
in a context-dependent manner, and led to 50%–70% reduction in PLOD2 expression in fibrotic
fibroblasts and in MDA-MB-231 cancer cells. Targeting KRAB to PLOD2 resulted in the deposition of
repressive histone modifications without DNA methylation and in almost complete PLOD2 silencing.
Interestingly, both long-term TGFβ1-induced, as well as unstimulated PLOD2 expression, was
completely repressed by KRAB, while M.SssI only prevented the TGFβ1-induced PLOD2 expression.
Targeting transiently expressed dCas9-KRAB resulted in sustained PLOD2 repression in HEK293T
and MCF-7 cells. Together, these findings point to KRAB outperforming DNA methylation as a small
potent targeting epigenetic effector for silencing TGFβ1-induced and uninduced PLOD2 expression.
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1. Introduction
Misregulation of epigenetic modifications is associated with aberrant gene expression profiles,
which contribute to the development or progression of a wide spectrum of diseases [1]. The enzymes
that catalyze epigenetic modifications have therefore been subjected to the intensive investigation
as potential targets for treatment [2]. However, as inhibitors of epigenetic enzymes can result in
genome-wide changes in chromatin and non-chromatin targets, these epi-drugs have undesired
side-effects. Therefore, gene-targeting approaches designed to locally interfere with transcriptional
activity provide promising alternatives to enzyme inhibitor strategies.
Several designer DNA binding platforms are currently applied for gene targeting, e.g., Zinc
Fingers Nucleases, TALENs, and CRISPR-Cas9 [3]. These platforms have been successfully repurposed
as targetable transcriptional modifiers by removing the nuclease domain/activity and tethering them to
transcriptional effectors or epigenetic enzymes. Targeted overwriting of epigenetic marks, referred to as
epigenetic editing (Figure 1A,B) [4], has been successfully applied in diverse therapeutic models [5,6],
however mitotic stability of the induced effects is still largely unclear.
Generally, therapeutic effects have been achieved by exploiting episomal (AAV) or integrative
(lentiviral) gene therapy vectors, which are increasingly accepted for gene editing in clinical trials [7],
but which do not allow to investigate the mitotic stability of the induced epigenetic effects. Using
Krüppel associated box (KRAB) as an effector domain, Thakore et al., showed silencing of Pcsk9,
a regulator of cholesterol levels, in the liver of adult mice for a duration of at least 24 weeks upon
delivery using AAV vectors [5]. However, as these delivery vectors are episomally maintained, it was
not possible to assess the mitotic stability of the effect of KRAB itself. The mode of action of KRAB
is to recruit KRAB-associated protein 1 (KAP-1), which in turn attracts H3K9me3 methyltransferase
SETDB1 (attracting Heterochromatin Protein 1 (HP1)) and the NuRD complex to deacetylate histones
and subsequently impact H3K4me3 levels [8]. Despite these indirect effects on the chromatin,
targeting KRAB generally represses gene expression in a transient manner in somatic cells [4,9–14].
For the induction of stable heterochromatin, direct editing of epigenetic marks e.g., DNA methylation
was assumed to be more effective [15,16].
There are contradictory reports on the sustainability of the changes induced by epigenetic editing:
For transcriptional activation, e.g., one study reported that the stability of the transcription induced by
exogenous writing of H3K4me3 histone modification is dependent on the endogenous DNA methylation
state [17]. Similarly, sustained repression was achieved using targeted DNA methylation in some
studies [10,15,18,19], but this could not be confirmed for other target genes [20,21]. These examples
show that the maintenance of epigenetic reprogramming is context-dependent.
The current consensus holds that for sustained effects of epigenetic reprogramming multiple
effector domains are required [12–14,22]. For clinical applications however, the requirement of multiple
components would be a serious limitation. Here, we tested two effector domains for their capability
to induce direct and indirect epigenetic modifications, (long-term) gene repression and the effect of
transcriptional activation on the induced heterochromatin.
We focused on a clinically important gene, Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase 2
(PLOD2), which has a progressive and metastasizing function in cancer [23]. PLOD2 is also an important
player in fibrosis, where it is induced by transforming growth factor beta-1 (TGFβ1) [24–26]. PLOD2,
also known as lysyl hydroxylase 2 (LH2), is a collagen biosynthesis enzyme that initiates pyridinoline
cross-links of collagens [27]. These cross-links prevent collagen degradation by proteinases and in turn
force a feedback loop that results in excessive accumulation of collagen and disease progression [24,28].
Attenuating PLOD2 expression has previously been shown to be a promising treatment against fibrosis
and cancer metastasis in preclinical settings [29–31]. However, current approaches are either not
selective for the PLOD2 gene or are exploiting methods that are clinically less favorable (e.g., gene
knockout) [28]. To induce repression of genomic PLOD2, we targeted the transcription factor KRAB
and variants of the CG-specific prokaryotic DNA methyltransferase M.SssI to the PLOD2 promoter
region. Our results show that the M.SssI-induced DNA methylation did not affect endogenous
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PLOD2 expression, but severely hampered the TGFβ1-induced activation of the gene. Interestingly,
the expression of PLOD2 was completely repressed by targeting of the transcriptional repressor KRAB
to the PLOD2 gene, even under conditions of continuous stimulation by TGFβ1.
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Figure 1. Screening of engineered transcriptional activators and repressors to target PLOD2. (A) Schematic
representation of the epigenetic editing strategy to modulate PLOD2 expression; (B) Schematic representation
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of the six-finger zinc finger (ZF) DNA binding domain with the fused effector domain Super Krüppel
associated box (KRAB) Domain (SKD) or VP64 flanked by a nuclear translocation signal (NLS);
(C) Approximate locations of the 8 ZFs binding sites in the PLOD2 gene ranging from the proximal
promoter to the first exon on both the leading and lagging strand. In the panel beneath, the CG island
CG island (CpG) sites are depicted as vertical bars and a CpG island (CGI) as a green horizontal bar.
(D) PLOD2 mRNA expression levels in human dermal fibroblasts (HDFs) transduced with retrovirus
to express the eight ZF-SKD fusion proteins, or with empty vector (EV) control (mean ± SEM; n = 3,
one-way ANOVA (* p < 0.05, ** p < 0.01, *** p < 0.001). (E) PLOD2 mRNA expression levels of
HDFs transduced with retrovirus for the eight ZF-VP64 fusion proteins or EV control (mean ± SEM;
n = 3, one-way ANOVA (* p < 0.05). (F) Western blot of Dupuytren’s patient-derived fibroblasts
after retroviral transduction of ZF7-NoED, ZF7-SKD, ZF8-NoED, ZF8-SKD or EV control, stained for
PLOD2 and YWHAZ as a loading control. (G) PLOD2 mRNA expression levels in HDFs after retroviral
expression of ZFs or EV control and stimulated with TGFβ1 for 2 days (mean ± SEM; n = 3, one-way
ANOVA (* p < 0.05).
2. Results
2.1. Engineered Transcription Factors Can Activate and Repress PLOD2 Expression
Eight modular six-finger zinc finger proteins (ZF1-ZF8) (Supplementary Figure S1) were engineered
to bind 18 bp sequences in the genomic locus of PLOD2 (Supplementary Figure S2), spanning a region
from −150 to +479 bp relative to the transcription start site (TSS) (Figure 1C, Supplementary Figure S2B).
To determine the efficiency of the ZF modules, we first expressed the eight ZFs fused to a variant of
the KRAB suppressor (Super KRAB Domain (SKD)) or the transcriptional activator VP64 (tetramer of
the Viral Protein VP16) (Figure 1B) in human dermal fibroblasts (HDFs). PLOD2 expression levels
were assessed 48 h after retroviral delivery. PLOD2 mRNA expression was repressed by fusions
of SKD to ZF2, ZF5, ZF6, ZF7, and ZF8 with ZF7 and ZF8 showing the strongest repression (70%,
Figure 1D). For VP64 fusions, the strongest effects were observed with ZF2 -ZF6, -ZF7 and -ZF8
(Figure 1E). For ZF1, -ZF3 and -ZF4 no effect was observed for either fusion. No clear correlation
was found between the expression of the respective ZF and the effect on PLOD2 mRNA expression
modulation (Supplementary Figure S3A). Based on this screening and their high protein expression
levels (Supplementary Figure S3C), we continued our studies with ZF7 and ZF8.
2.2. ZF Repressors Attenuate Fibrosis-Related PLOD2 Expression
As our aim was to repress PLOD2 in fibrotic fibroblasts, we assessed the effects of ZF-SKD fusions
in patient-derived fibroblasts. We obtained fibrotic fibroblasts from a patient with Dupytren’s disease,
a disabling fibrotic condition of the hand, where the palmar fascia is chronically affected by fibrotic
tissue, and which results in a contracting phenotype restricting the motion of one or more fingers.
Fibroblasts isolated from the affected palmar fascia were transduced to express ZF-SKD fusions. In this
disease model, PLOD2 protein production was strongly repressed at day-two post-infection when
compared to the ZF without effector domain (NoED) and the empty vector (EV) controls (Figure 1F).
Using our healthy HDF model, we could simulate the fibrosis-related increase in PLOD2 expression by
TGFβ1. In the continuous presence of TGFβ1, both ZF-SKD fusions significantly repressed TGFβ1-induced
PLOD2 mRNA expression by 65%, five days post retroviral infection, whereas no effects were seen for
the NoED and EV controls (Figure 1G). As TGFβ1 stimulations had no negative effects on ZF expression
(Supplementary Figure S3B), this in vitro fibrosis model was used in further experiments.
2.3. Both ZF-SKD as Well as ZF-M.SssI Induce Efficient Repression of PLOD2 in Fibroblasts
To ensure the expression of the tested epigenetic effectors in all analyzed cells, we created HDF cell
lines carrying stably integrated TET-ON doxycycline responsive transgene cassettes encoding one of
the ZF-SKD, ZF-M.SssI and ZF-M.SssI∆∆ fusion proteins (Figure 2A). M.SssI is a CG-specific prokaryotic
Int. J. Mol. Sci. 2020, 21, 3634 5 of 24
DNA (cytosine-5) methyltransferase and M.SssI∆∆ is an inactive double mutant (Y137F+C141S) of M.SssI.
M.SssI∆∆ was used as the negative control. Treatment of the cells with doxycycline for two days resulted in
increased ZF-SKD and ZF-M.SssI mRNA expression (Figure 2B). Two days after doxycycline withdrawal,
expression of the fusion genes dropped back to pre-induction levels (e.g., cycle thresholds for ZF7-SKD
expression range from Ct = 25 before Dox, to Ct = 19 after two days of Dox treatment (Dox day 2), back to
Ct = 24 after two days subculturing (Day 2); compared to YWHAZ which yields Ct values of 20 in
these qRT-PCR experiments). Efficient protein expression of the ZF-SKD fusions was detected two days
after doxycycline withdrawal (Figure 2C), whilst the expression was no longer detectable after 10 days.
The HA-tagged ZF7 and ZF8 NoED or fused to SKD were highly enriched at the targeted DNA region of
PLOD2 confirming efficient binding to the addressed sites (Figure 2D).
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6-finger ZF with NLS in between. (B) mRNA expression levels of ZF-SKD or ZF-M.SssI fusions
in HDFs engineered to express ZF-fusions treated with doxycycline for two days (Dox Day2)
and stimulated with TGFβ1 for additional 2 and 10 days (mean ± SEM; n = 3, unpaired Student’s t-test
(*** p < 0.001)). (C) Western blot of transgenic HDFs after doxycycline treatment for two days (Dox
Day 2), and subsequent TGFβ1 stimulation for 2 and 10 days (Day 2, Day 10), compared to non-dox
treated cells (lanes labeled as “-”). Stained for His-tagged ZF7-SKD and ZF8-SKD and YWHAZ as
a loading control. (D) qChIP assay with an antibody against HA-tag to reveal binding of the ZFs
at the target region (+326/+447) directly following the 2 days of doxycycline treatment. (E) Scheme
of the experimental procedure: transgenic HDFs were treated with doxycycline for 2 days (Dox
Day 2), followed by 2 or 10 days of stimulation with TGFβ1 or vehicle control. (F) PLOD2 mRNA
expression levels of transgenic HDFs after doxycycline treatment and stimulation with TGFβ1 or
control (PBS with BSA and citric acid) for 2 days (mean ± SEM; n = 3, one-way ANOVA (*** p < 0.001;
ns = not significant)). (G) PLOD2 mRNA expression levels of transgenic HDFs after doxycycline
treatment and stimulation with TGFβ1 or control for 10 days (mean ± SEM; n = 3, one-way ANOVA
(*** p < 0.001; ns = not significant)). Statistical differences were compared to EV stimulated with TGFβ1.
(H) Western blot of transgenic HDFs treated with doxycycline and stimulated with TGFβ1 for 2 days,
stained for PLOD2 and YWHAZ as a loading control. (I) PLOD2 protein expression in transgenic
HDFs treated with doxycycline and subsequently stimulated with TGFβ1 for 10 days, determined by
immunocytochemistry and quantified by TissueFAXS relative to DAPI as a percentage of positive cells.
Depicted white bars represent 20 µm.
The effects of ZF-SKD and ZF-M.SssI expression was studied under two conditions: in transgenic
HDF cells in which PLOD2 expression was induced with the transcriptional activator TGFβ1, and in
transgenic HDF cells, which were not treated with TGFβ1 (carrier). Expression of the ZF-SKD
fusions resulted in almost complete prevention of TGFβ1-induced as well as unstimulated PLOD2
mRNA expression, and this strong repression was detectable even after 10 days of continuous
TGFβ1-stimulation (Figure 2F,G). In contrast, the expression of the ZF-M.SssI fusions prevented
TGFβ1-induced PLOD2 mRNA levels only by 50% on day 2 (Figure 2F), and this effect was present
at day 10 for ZF7-M.SssI, but not for ZF8-M.SssI (Figure 2G). As expected, NoED controls or
the catalytically inactive MS∆∆ had no effect on the TGFβ1-induced PLOD2 mRNA expression.
Interestingly, non-stimulated PLOD2 expression (carrier control without TGFβ1 stimulation) was
repressed only by SKD fusions, which suggests that targeted DNA methylation can be used to repress
fibrosis-specific overexpression of PLOD2, leaving the physiological expression levels unaltered.
Importantly, neither TGFβ1-stimulation alone (Supplementary Figure S4A), nor in combination with
ZF-SKD expression (Figure 2I) had adverse effects on cell morphology.
Changes detected at the mRNA level were reflected at the protein level. After two days of Dox
treatment and two additional days of continuous TGFβ1 stimulation, no PLOD2 protein was detectable
by Western blot in cells engineered to contain the ZF-SKD transgene, whereas a substantial reduction
in PLOD2 protein was observed for cells engineered to contain the ZF-M.SssI transgene (Figure 2H).
Importantly, also after 10 days of TGFβ1 stimulation, immunocytochemistry and quantification of
positive cells confirmed that PLOD2 was repressed (by ~99% for both ZF-SKD and 50% for ZF7-M.SssI
(Figure 2I, Supplementary Figure S4B)). Collectively, the mRNA, as well as the protein levels, showed
effective PLOD2 repression, even after 10 days of continuous expression stimulation, for both ZF-SKDs
as well as for ZF7-M.SssI in our fibrosis model.
2.4. PLOD2 Repression is Associated with Epigenetic Modulation in TGFβ1 Stimulated Fibroblasts
To identify the epigenetic changes that underlie the observed PLOD2 repression, we first analyzed
two regions of the PLOD2 gene for histone modifications in doxycycline-treated HDFs after two
days of TGFβ1 stimulation (Figure 3A). One of the investigated regions (from +326 to +447 bp
relative to TSS) contained the target sites of ZF7 and ZF8, whereas the other region (from −796 to
−686 bp) was located ~1kb upstream. For both SKD fusions, a reduction of the gene activation-related
modifications H3ac and H3K4me3, and an increase of the repression-related modifications H3K9me3
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and H3K27me3 were observed at the target region (from +326 to +447), as well as at the −796 to
−686 bp upstream region (Figure 3B). Targeting M.SssI by the zinc fingers ZF7 and ZF8 also reduced
H3K4me3, and increased H3K27me3 and H3K9me3 levels at both regions compared to cells targeted
with the catalytically-inactive M.SssI∆∆ (Figure 3C).
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Figure 3. Induced PLOD2 repre i accompanied by repressive histone mod fications in human
dermal fibroblasts stably engineered to express the indicated ZF-fusions. (A) Schematic representation
of the PLOD2 target regions detected by qPCR (+326 to +447 and −796 to −686)) upon chromatin
pull-down using the indicated antibodies (qChIP). (B) qChIP assay with antibodies against H3ac,
H3K4me3, H3K9me3 and H3K27me3 of the indicated transgenic cells after 2 days of stimulation with
TGFβ1. (C) qChIP assay with antibodies against H3K4me3, H3K9me3, H3K27me3 of the indicated
transgenic cells after 2 days of stimulation with TGFβ1. (D) qChIP assay with antibodies against
histone 3 (H3) of the indicated transgenic cells after 2 days of stimulation with TGFβ1. (E) qChIP assay
with antibodies against H3ac, H3K4me3, H3K9me3 and H3K27me3 of the indicated transgenic cells
after 10 days of stimulation with TGFβ1. Data are shown as mean ± SEM; n = 3, unpaired two-tailed
Student’s t-test (* p < 0.05, ** p < 0.01, *** p < 0.001).
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Furthermore, both SKD and M.SssI targeted cells showed enrichment of Histone 3 (Figure 3D),
suggesting enhanced nucleosome occupancy predominantly at the target site. To test the resilience of
the epigenetic modulations indirectly induced by SKD, we analyzed activating and repressive histone
marks in doxycycline-treated cells after 10 days of continuous TGFβ1 stimulation of PLOD2 expression.
We again observed a significant reduction of H3ac and H3K4me3, and significant enrichment of
H3K9me3 and H3K27me3 compared to EV at both regions (from −796 to −686 and from +326 to +447)
(Figure 3E), even though the cells had a severely reduced proliferation rate during serum starvation
(Supplementary Figure S5). These data show that the repressive chromatin environment induced by
targeting ZF-SKD fusions is resilient to long-term stimulation with TGFβ1.
Bisulfite sequencing of the +57 to +544 bp region of the PLOD2 gene (Figure 4A) detected efficient
de novo DNA methylation in cells expressing ZF7-M.SssI or ZF8-M.SssI after two days of TGFβ1
stimulation (Figure 4B). For ZF7-M.SssI the level of DNA methylation increased even further after ten
days of stimulation (Figure 4C). Extensive methylation was detected throughout the analyzed region
without a clear methylation peak adjacent to the targeting sites. Interestingly, ZF8-M.SssI expressing
cells showed similar DNA methylation levels at day 2 and day 10, which contrast with the loss of
transcriptional repression by day 10 (Figure 2G,I). Despite the fact that targeting SKD resulted in very
effective PLOD2 repression, only low levels of DNA methylation were induced (3.7% for ZF7-SKD
and 5.7% for ZF8-SKD compared to 0.4% for EV and up to 1.5% for NoED (Figure 4D)). Taken together,
an increase in DNA methylation could be observed for both ZF7-M.SssI and ZF8-M.SssI, and not for
the ZF-SKD fusions, confirming that the M.SssI and SKD effector domains induce PLOD2 repression
via different regulatory mechanisms.
2.5. SKD- and M.SssI-Induced Epigenetic Modulation in Highly Proliferative Breast Cancer Cells
To further validate the epigenetic modulation potential of SKD and M.SssI, we stably integrated
the ZF-SKD and ZF-M.SssI fusion genes into the genome of highly proliferating MDA-MB-231 breast
cancer cells, in which high PLOD2 expression was shown to be associated with metastatic potential [30].
To reduce potential off-target DNA methylation induced by WT M.SssI, we included the C141S mutant
of M.SssI, which has ~1% activity of the wild type enzyme [32–34]. In these experiments, ZF7 was
used as a targeting domain since this was the most efficient DNA binding domain in our HDF system.
After doxycycline treatment for two days, the cells were subcultured for an additional 2 and 20 days in
regular medium (Figure 5A), at which time points the cells were assessed for any remaining expression
of ZF-fusions (Figure 5B), and for epigenetic changes at two regions (Figure 5C).
We first tested epigenetic changes by chromatin immunoprecipitation. H3K4me3 levels at the ZF7
binding region (from +326 to +447) were reduced by ~58% in ZF7-SKD expressing cells, and to a lesser
extent by the different ZF7-M.SssI derivatives at day 2 (Figure 5D). A similar reduction of H3K4me3
levels for both ZF7-SKD and ZF7-M.SssI compared to EV was detected in the −796 to −686 region.
Again, ZF-SKD expressing cells showed strong enrichment in H3K9me3 and in H3K27me3 at both
investigated regions as compared to EV expressing cells (Figure 5D). In contrast to our observations in
HDFs (Figure 3C), targeting of M.SssI WT to the PLOD2 region in MDA-MB-231 cells did not result in
secondary changes of H3K9me3 and H3K27me3 levels two days after doxycycline removal. This could
be due to differences in growth kinetics, which entails a much faster turnover of MDA-MB-231 cells,
or to the continuous TGFß1 stimulation applied to the HDFs but not to the MDA-MB-231 cells.
After 20 days of subculturing the cells in a regular medium, we found reduced levels of
the activating signal H3K4me3 in both analyzed regions of the SKD- and M.SssI-targeted cells, but
not in cells expressing ZF7-C141S or ZF7-MS∆∆ (Figure 5E). In SKD-targeted cells, clear enrichments
of the repressive marks H3K9me3 and H3K27me3 were seen. In contrast, ZF-M.SssI targeted cells
showed no enrichment of these histone modifications (Figure 5D,E).
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in human dermal fibroblasts. Open circles represent unmethylated CpGs, closed circles represent
methylated CpGs. The total percentage of DNA methylation is shown on the right side of the panels.
(A) Schematic representation of the region probed for methylation (from +57 to +544 relative to
the transcriptional start site). The numbers 7 and 8 indicate approximate positions of the target sites
for the zinc fingers ZF7 and ZF8, respectively. (B) Cells stably engineered to contain the ZF-M.SssI
transgene. Methylation was determined after two days of Dox treatment followed by two days of
TGFβ1 stimulation. (C) The same as B, but methylation was determined after ten days of TGFβ1
stimulation. (D) Cells stably engineered to contain the ZF-SKD transgene. Methylation was determined
after two days of Dox treatment followed by ten days of TGFβ1 stimulation.
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Figure 5. Targeting SKD, but not M.SssI, introduces repressive histone modifications in transgenic 
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Figure 5. Targeting SKD, but not M.SssI, introduces repressive histone modifications in transgenic
MDA-MB-231 cells. Expression of ZF-fusions in MDA-MB231 cells stably engineered to contain
the indicated transgenes, after treatment with doxycycline for 2 days and subcultured for an additional
2 and 20 days. (A) Schematic representation of the experimental procedures for TET-ON MDA-MB-231
transgenic cells; (B) mRNA expression levels of ZF-SKD or ZF-M.SssI fusions in transgenic MDA-MB-231
cells treated with or without doxycycline for two days followed by 2 or 20 days subculturing.
The specificity of the primers is indicated by the absence of expression in ZF7-NoED cells. (C) Schematic
representation of PLOD2 with the ZF7 target site and areas detected by qChIP. (D) qChIP assay on
transgenic cells subcultured for 2 days using antibodies against H3K4me3, H3K9me3 and H3K27me3,
represented as enrichment against input DNA (mean ± SEM; n = 3, one-way ANOVA * p < 0.05,
** p < 0.01, *** p < 0.001). (E) qChIP assay on transgenic cells subcultured for 20 days using antibodies
against H3K4me3, H3K9me3 and H3K27me3, represented as enrichment against input DNA (mean ±
SEM; n = 3, one-way ANOVA (* p < 0.05, ** p < 0.01, *** p < 0.001)).
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Next, DNA methylation changes were analyzed in two regions (from −443 to −372 and from
+349 to +443) of the PLOD2 gene (Figure 6A). After two days of subculturing the cells in regular
medium, an increase of DNA methylation by M.SssI was observed at all assessed CpGs upstream of
the PLOD2 transcription start site (Figure 6B) and within the ZF targeting region (Figure 6C). Based on
the absolute levels, the de novo DNA methylation was the highest around the targeting site and faded
towards both extremities. Interestingly, targeting C141S induced significant methylation of one specific
CpG site at the ZF target region of PLOD2 (Figure 6C). SKD and the catalytically inactive MS∆∆
did not significantly affect DNA methylation in these regions. DNA methylation in both PLOD2
regions of the M.SssI targeted cells were present after 20 days of subculturing (Figure 6D,E), while
the other targeted M.SssI derivates did not affect DNA methylation at the PLOD2 promoter at day 20.
Taken together, these data indicate that M.SssI induce strong DNA methylation without repressive
histone modification cross-talk in MDA-MB-231 breast cancer cells, whereas SKD induced pronounced
heterochromatin features without DNA methylation.
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Figure 6. Targeting M.SssI induces strong a d long-range DNA methylation in transgenic MDA- B-231
cells. MDA- B-231 cells, stably engineered to contain the indicated transgenes, were t at d with
doxycycline for 2 days and subcult red for an dditional 2 and 20 days. (A) Schematic representation
of the PLOD2 locus. The approxi ate l c ti s f t e F7 binding site, the transcriptional start
size, and the two regions (−443 to −372 and +349 to +443) analyzed for induced DNA methylation
are indicated. (B–E) DNA CpG methylation levels quantified by pyrosequencing (B) region −443 to
−372, two days after doxycycline withdrawal; (C) region +349 to +443, two days after doxycycline
withdrawal; (D) region −443 to −372, 20 days after doxycycline withdrawal; (E) region +349 to +443,
20 days after doxycycline withdrawal. All pyrosequencing data are depicted as mean ± SEM; n = 3,
two-way ANOVA * p < 0.05, ** p < 0.01, *** p < 0.001.
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2.6. ZF-SKD and ZF-M.SssI-Induced Repression of PLOD2 in Highly Proliferative Breast Cancer Cells
Next, we were interested in the functional effect of the rewritten epigenetic marks in
the MDA-MB-231 cells engineered to contain the ZF-fusion transgenes. For transgenic MDA-MB-231
cells, we observed that SKD targeting resulted in almost complete inhibition of PLOD2 mRNA
expression, after ten or twenty days of subculturing in regular medium, while M.SssI targeting
reduced PLOD2 mRNA expression by ~80%, compared to cells expressing EV (Figure 7A). The C141S
and the MS∆∆ mutants of M.SssI did not affect PLOD2 mRNA expression. Based on other reports using
this system [15,35], these data seem to indicate that SKD and M.SssI-induced repression of PLOD2 is
sustained in these highly proliferative breast cancer cells. Yet, since leakiness is an often-observed
phenomenon for the TET ON system, we measured the PLOD2 expression also in cells that were not
treated with doxycycline and found that the background levels of ZF-fusions (Figure 5B) seemed
sufficient to induce similar levels of PLOD2 repression as observed for Dox-supplemented conditions
(Figure 7B). This observation of highly effective uninduced low-dose SKD-mediated PLOD2 silencing
was also observed for another breast cancer cell line at day 2 (MCF-7, Supplementary Figure S6) and for
days 10 and 20, time points of the transgenic MDA-MB-231 cells (Supplementary Figure S7A).
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Figure 7. Repression of PLOD2 by targeting SKD or M.SssI to the PLOD2 promoter in transgenic
MDA-MB-231 cells. (A) PLOD2 mRNA expression levels in MDA-MB-231 cells, engineered to contain
the indicated transgenes, treated with doxycycline for 2 days and subcultured in normal medium for
10 and 20 days (mean ± SEM; n = 3, one-way ANOVA ** p < 0.01, *** p < 0.001). (B) PLOD2 mRNA
expression levels in the transgenic MDA-MB-231 cells treated with or without doxycycline for 2 days
and subcultured in normal medium for 2 days.
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Given that other studies [9,12,15] clearly showed a transient nature of SKD-induced repression,
we set out to explore leakiness of the expression of EDs in our system and its effects on PLOD2
expression in more detail (Supplementary results and Supplementary Figures S8 and S9). In short,
in our experimental setup, the TET ON stable cell line system does not allow conclusions on
the sustainability of SKD- or M.SssI-induced effects on PLOD2 expression as repression was observed
also without Dox treatment in various conditions and at longer time points (up to day 45).
2.7. SKD and M.SssI-Induced Repression of PLOD2 Using the Transient CRISPR-dCas9 Platform
Sustainability of SKD- and M.SssI-induced PLOD2 repression was studied using a transient
CRISPR gRNA expression system with dCas9 fused to SKD or to variants of MSssI, either constitutively
expressed or also transiently expressed after plasmid transfection. PLOD2 mRNA levels were measured
at day 2 and day 12. Day 12 was chosen for assessing sustainability because by day 12 the expression
of sgRNAs has faded out (Supplementary Figure S10A).
First, transient transfections were performed to express sgRNAs (g1-4) targeting PLOD2 in
HEK293T cells, engineered to constitutively express dCas9 only (NoED) or dCas9 fused to SKD,
to the inactive mutant of M.SssI (E186A), or to M.SssI-Q147L (which has ~10% activity of wild
type M.SssI). The lower DNA binding affinity of Q147L has been proven to increase the specificity
of targeted DNA methylation over the wildtype M.SssI [34]. To assess whether direct writing of
H3K9me would result in sustained effects, as previously shown [36], HEK293T cells constitutively
expressing dCas9 fused to the H3K9 methyltransferase G9A (or dCas9 fused to a catalytic inactive
G9A (G9A mutant [37]) were used. In the HEK293T-dCas9-SKD cells, an initial repression of PLOD2
was observed two days after the transfection of the PLOD sgRNAs, as compared to EV controls
(Figure 8B). Of note, the induced repression is far less effective in the dCas9-SKD expressing cells
compared to the ZF-SKD expressing cells as for cells expressing dCas9-SKD, the sgRNAs need to
be delivered by transient expression plasmids. The repression was sustained and even further
reinforced 12 days after transfection of sgRNAs (from 17.5% to 26.8%). In the M.SssI(Q147L) transgenic
cell line initially no PLOD2 repression was observed upon transfection with sgRNA plasmids g1-4
when compared to the empty guide transfection control. After 12 days, however, a repression of
25.5% could be observed in cells transfected with PLOD2 guide plasmids compared to empty guide
transfection control, which was not observed for M.SssI(E186A) (Figure 8B). Furthermore, the potential
of dCas9-G9A to induce sustained PLOD2 repression was also investigated in different cell types (HeLa
and MCF-7, Supplementary Figure S10B), but no significant repression could be observed compared
to the catalytically inactive dCas9-G9A mutant. Of note, for MCF-7 cells stably expressing G9A or
its mutant, a 50% reduction in PLOD2 expression was observed for PLOD2 g1-4 compared to empty
guide control transfections (Supplementary Figure S10B).
Next, we engineered stable constitutively dCas9-SKD expressing MCF-7 cells and transiently
transfected plasmids expressing the PLOD2 sgRNAs or the sgRNA empty vector. In these cells,
SKD targeting of PLOD2 led to sustained repression 14 days after PLOD2 sgRNA transfection
(Supplementary Figure S10C). Of importance, targeting another gene (SPEDF) in the same set
of experiments did not lead to sustained repression, indicating that the PLOD2 gene might be
particularly sensitive to repression by KRAB-induced mechanisms and that KRAB effects are
chromatin context-dependent.
We also investigated whether transfecting other sgRNAs (PLOD2 g5-7) targeted to different
positions in the PLOD2 promoter (Figure 8A), or whether combining the four sgRNAs into one tandem
plasmid (instead of using a mix of four separate plasmids) could improve the repression of PLOD2 in
HEK293T-dCas9-SKD cells. Only transfecting the combination of four separate plasmids expressing
the guides PLOD2 g1-4 resulted in significant repression (Supplementary Figure S10D).
Collectively, upon targeting PLOD2 in engineered HEK293T cells, SKD led to sustained repression,
while repression induced by M.SssI seems to take a longer time (detectable after 12 days).
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Figure 8. Sustained repression of PLOD2 by SKD targeted to the PLOD2 promoter by CRISPR-dCas9 in
HEK293T cells. (A) Schematic representation of the PLOD2 locus with binding locations of the sgRNAs
(g1-7). (B) PLOD2 mRNA expression levels in HEK293T cells constitutively expressing the indicated
dCas-fusions, 2 and 12 days after transient transfection with sgRNA g1-4 plasmids. Data are shown
relative to the PLOD2 expression in the respective transgenic cells upon transfection with plasmids
expressing “ mpty” guide RNA vector (EV), set at one for each stable cell line. (C) PLOD2 mRNA
expression levels of wild-type HEK293T cells, 2 and 12 days fter transient transf ction with plasmids
encoding the indicated gRNAs and dCas9-SKD (blue bars). Data ar shown relative to PLOD2
expression i cells transfected with plasmids expres ing all gRNAs and dCas9-NoED (No Effector
Domain), set a 1 (purple bar). EV (empty vector) refers to sgRNA plasmid without the targeting
nucleotides. D ta are the mean ± SEM of biological triplicates, diff ence are analyzed using unpaired
two-tailed Student’s t-test vs. EV (B) or vs. dCas9-N ED (C); * < 0.05 ** p < 0.01.
Finally, to confirm the sustained character of the SKD-induced PLOD2 repression, we transfected
the plasmids to express dCas9-ED s well as the sgRNAs into wildtype HEK293T cells. Transient
expression of dCas9-SKD and PLOD2 g1 4, result d in sustained repression previously seen in
stable dCas9-SKD-expressing cells. The SKD-induced pressio was ev n mo efficient in this
system compared to the stable dCas9-SKD expressing cells with 46.3% repression after two days,
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compared to 17.5% repression in stable HEK293T-SKD. Importantly, also after transient transfection,
PLOD2 repression was sustained with 23.8% repression for at least 12 days (Figure 8C). Combining
the PLOD2 tandem with PLOD2 g5-7, to cover a larger region within the PLOD2 gene, did not lead
to a significant downregulation of PLOD2 (Figure 8C, Supplementary Figure S10D). In summary,
using the truly transient CRISPR-dCas9 system, we showed that SKD is sufficient to induce sustained
PLOD2 repression.
3. Discussion
In this study, we showed that targeting the KRAB domain (SKD) can lead to the silencing of
the PLOD2 gene without the induction of DNA methylation, even under continuous expression
stimulation by TGFβ1. DNA methylation-induced by M.SssI did inhibit the TGFβ1-induced expression
of PLOD2 repression, while not affecting the constitutive PLOD2 expression. By using the transient
CRISPR-dCas9 platform we showed that targeting of SKD, or an M.SssI derivative, to PLOD2 might be
sufficient to achieve mitotically stable gene repression. As such, epigenetic editing using either of these
effector domains has the potential to evolve into anti-PLOD2 therapeutics against fibrosis. Interestingly,
targeted DNA methylation to inhibit PLOD2 expression might even leave healthy cells unaffected. Yet,
further research using these tools will be needed to unravel the differential clinical advantages.
The current paradigm of KRAB induced repression holds that transcriptional effects are transient
in somatic and cancer cells [4,9–13,22,38]. This transient nature of repression has been confirmed
in transgenic mice using a drug-controllable KRAB repressor that targets the endogenous Hprt
gene [39]. In contrast, multiple other studies showed a developmental-stage dependent effect of
KRAB, where the expression of KRAB-repressors during early embryonic development induced stable
repression, while expression at later stages of development resulted in reversible silencing [40–43].
Interestingly, in iPSCs, which are considered as embryonic models, KRAB-induced repression was
fully reversible [44]. The stability of KRAB-induced gene repression in early stages of embryonic
development was attributed to de novo DNA methylation, indirectly induced by KRAB [40,42,43].
When HP1 was targeted directly to Oct4 or to reporter plasmids in embryonic stem cells, sustained
DNA methylation was observed, which was associated with sustained repression in the absence
of transcriptional activation [45,46]. Interestingly, also in these studies a clear context-dependency
was observed regarding stable epigenetic reprogramming. De novo DNA methylation upon KRAB
targeting was not detected in somatic cells [42,47]. Our study confirms the lack of DNA methylation in
somatic cells upon targeting KRAB to PLOD2. This finding on longer-term KRAB-induced PLOD2
epigenetic reprogramming in somatic cells is in contrast with studies showing that DNA methylation
is required for maintenance of silencing [12–14,46,48].
Unraveling context-dependent effects is of importance as current understanding dictates that
a combination of different repressive effector domains is needed for epigenetic editing to achieve
sustained gene repression [12–14,22]. Although upon random integrations of GFP reporter cassettes,
some genomic loci seemed responsive to KRAB for long-term silencing, Amabile et al. showed
that Dnmt3A, Dnmt3L and KRAB together are superior over individual and two effector domain
approaches in achieving long-term gene repression. Indeed, the three domains were required to
ensure the repressive epigenetic state associated with long-term silencing of three endogenous genes
(B2M, IFNAR VEGFA) [12]. Similarly, these EDs, when fused together in a single TALE-based fusion
protein, led to robust and sustained silencing of CXCR4 (although not of CCR5), accompanied by
reduced chromatin accessibility and increased promoter methylation [14]. By using the CRISPR
platform, O’Geen et al. showed that co-targeting of dCas9-KRAB and dCas9-Dnmt3A3L can induce
long-term repression for some genes [13]. Importantly, these authors also presented examples of
genes that could not be repressed by this combination. In this respect, a combination of Dnmt3A3L
and EZH2 (but not KRAB) was later demonstrated to be required to stably repress HER2, while
again Dnmt3A3L and/or KRAB were sufficient to induce long-term repression of SNURF [22].
To understand context-dependent epigenetic transcription regulation, which involves both stable
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sustained and dynamic flexible aspects, models to obtain a mechanistic understanding of its systems
behavior are needed. Quantitative measurements of targeted epigenetic editing with read-outs
at real-time, single-cell and single-molecule level combined with dynamic computational models are
important to formulate and verify mechanistic models. Our current epigenetic editing study provides
directions for such a quantitative model-driven approach.
Despite the yet unknown context-dependent requirements for gene silencing, epigenetic editing
is considered to require more than KRAB to maintain silencing [12–14,22]. Here, we provide evidence
that KRAB targeting alone might be sufficient to induce longer-term gene repression for certain
genomic loci. Although KRAB proteins do not have catalytic activity themselves, they are considered
strong indirect inducers of heterochromatin. In addition to the increase of H3K9me3 associated with
the targeted region after ZF-KRAB expression, we also observed an increase of H3K27me3, which was
in line for example with the observation that targeting KRAB to enhancers resulted in H3K27me3
at its interacting promoter [49]. This effect might relinquish the need for DNA methylation to achieve
stability of KRAB-induced repression.
Despite the efficient DNA methylation induced by M.SssI, PLOD2 repression was less pronounced
(50% in fibroblasts; 75% in cancer cells) than SKD-induced repression (99% in both fibroblasts and cancer
cell). Interestingly, in low-proliferating fibroblasts, but not in cancer cells, M.SssI induced repressive
histone marks, in an almost similar pattern as SKD. However, the absolute level of these epigenetic
modifications was lower for M.SssI, which was in line with the lower efficiency of M.SssI-induced
transcriptional repression of PLOD2. Furthermore, targeting M.SssI did not repress unstimulated
PLOD2 expression, whilst both SKD fusions repressed PLOD2 expression also in unstimulated
conditions. This difference in effect might offer an advantage to targeted DNA methylation as
an innovative clinical anti-fibrosis approach, although as for all epigenetic editing approaches,
the specificity of the induced effects needs to be considered. As M.SssI is a highly active enzyme that
generates broad methylation patterns [34], we included less active variants (e.g., C141S which has 1%
activity of wild type M.SssI). Indeed, we could show induced methylation of only one CpG in the region
where the C141S effector domain was predicted to be targeted, as was also observed by us previously
using a different DNA binding platform [32]. However, methylation of this single CpG had no profound
effect on chromatin modifications and transcriptional activity. When targeting Q147L (which has 10%
activity of wildtype M.SssI enzyme) fused to dCas9 [50], we could observe downregulation of PLOD2
expression. Downregulation was not observed with targeting the catalytically inactive mutant E186A,
indicating that the repressive effect is not due to steric hindrance by dCas9 fusions.
Altogether, our results could imply that to achieve sustained repression of the PLOD2 gene using
the M.SssI enzyme, a threshold amount of DNA methylation has to be written and/or CpGs critical for
transcription initiation need to be methylated. For PLOD2, a targeted methylation of 48.7% by ZF8
(Figure 4C), was not sufficient for significant repression after 10 days of TGFβ1 treatment in HDFs
(Figure 2G), whilst a methylation of 63.4% by ZF7 did repress PLOD2 in a significant manner. KRAB
targeting alone did not result in increased methylation. This indicates that the KRAB-induced repressive
effect for PLOD2 is achieved through different (epigenetic) mechanisms, like the observed increase
in H3K9me3 and H3K27me3, allowing innovative approaches to design small, single-component
repressors to interfere with fibrosis.
4. Materials and Methods
4.1. Cell Culture and Stimulation
Human skin fibroblasts (adult donor) were obtained from American Type Culture Collection
(ATCC, Manassas, VA, USA) (CCD-1093SK) and cultured for up to 12 passages in EMEM (Lonza,
Basel, Switzerland) supplemented with 10% heat inactivated fetal bovine serum (FBS) (Thermo Fisher
Scientific, Waltham, MA, USA), penicillin/streptomycin (Lonza) and l-glutamine (Lonza). Fibroblasts
isolated from the palmar fascia of a Dupuytren’s patient (according to Declaration of Helsinki
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principles) were a kind gift from Prof. Dr. P.M.N. Werker (University Medical Center Groningen,
the Netherlands), and were cultured in DMEM (Lonza) supplemented with 10% heat-inactivated
FBS, penicillin/streptomycin (Lonza) and l-glutamine (Lonza) for up to 6 passages. MDA-MB-231
breast cancer cells and Human embryonic kidney cells (HEK293T) were obtained from ATCC
(CRM-HTB-26 and CRL-3216, respectively), and cultured in DMEM supplemented with 10% FBS,
penicillin/streptomycin and l-glutamine. For experimental conditions the day after seeding, skin
fibroblasts were serum-starved by a complete medium with 0,5% FBS (Thermo Fisher Scientific), 18 h
prior to TGFβ1 stimulation. Recombinant human TGFβ1 (PeproTech, Rocky Hill, NJ, USA) was
dissolved in 10 mM citric acid (Sigma Aldrich, St. Louis, MO, USA) pH 3.0 and diluted 20 fold with
PBS supplemented with 0.1% bovine serum albumin (BSA) (Sigma Aldrich) to reach a concentration of
5 µg/mL. During all experimental procedures, the medium containing TGFβ1 (10 ng/mL) or an equal
amount of vehicle control was refreshed daily.
4.2. Zinc Finger Design and Cloning
For targeting the PLOD2 promoter by ZF technology, eight target regions, designated ZF1
t/m ZF8, were selected based on proximity to the TSS (RefSeq annotation) and on high-affinity
predictions with the help of www.zincfingertools.org. DNA encoding the eight modular six-finger ZFs
(Supplementary Figure S1) were synthesized (Bio Basic, Markham, ON, Canada) and subsequently
cloned in the retroviral vector pMX-IRES-GFP either without effector domain (NoED) or containing
the gene activator VP64, the transcriptional repressor SKD, or the DNA methyltransferase M.SssI.
The latter effector domain was generated by PCR (Phusion Hot Start II High-Fidelity DNA polymerase,
Thermo Fisher Scientific) on a previously described M.SssI carrying plasmid [33] using construct-specific
PCR primers flanked with cloning restriction sites and ligated into the pMX-IRES-GFP with T4 ligase
(Thermo Fisher Scientific). The less active derivatives of M.SssI (C141S and Q147L) and the inactive
(double) mutant (E186A or Y137F+C141S) were acquired previously by site-directed mutagenesis [33].
ZF7 and ZF8 constructs were subcloned in the Retro-X TET-ON advanced doxycycline-inducible
expression system (Takara Bio, Otsu, Japan).
4.3. Constructing dCas9 Fusions and Guide RNA Expression Plasmids
The plasmids pMLM3705 encoding the fusion protein dCas9-VP64 (Addgene, Watertown,
MA, USA: plasmid #47754) and pMLM3636 used to express a single-chain guide RNAs (Addgene:
plasmid #43860) were kind gifts from Keith Joung. Plasmids encoding single guide RNAs targeting
PLOD2 were generated by cloning 20 bp double-stranded oligonucleotides (see Supplementary Table S3)
into BsmBI-digested pMLM3636.
The plasmids pM-dCas9-MSssI(Q147L) and pM-dCas9-MSssI(E186A), which transiently express
the dCas9-MSssI(Q147L) or the dCas9-MSssI(E186A) fusion proteins in mammalian cells, were
constructed by first cloning the M.SssI(C141S) allele into pdCas9-NED [51] (Addgene: plasmid
#109358). The Q147L and E186A variants were created by fragment replacement using previously
described M.SssI mutants [50]. The plasmids pHAGE EF1α dCas9-MSssI(Q147L) and pHAGE EF1α
dCas9-MSssI(E186A) were used to stably integrate these transgenes into the genome of mammalian
cells. The plasmids were constructed by cutting out the M.SssI(Q147L) and M.SssI(E186A) genes
with SgsI(AscI) and PacI restriction enzymes (both; Thermo Fisher Scientific) and cloning them in
the pHAGE EF1α dCas9-NED (Addgene: plasmid #109369) vector between the AsiSI and MluI sites as
described before [52].
4.4. Viral Infections and Generating Stable Cells
For retroviral transduction of both types of fibroblasts with pMX-IRES-GFP, HEK293T cells seeded
in 10cm dishes were transfected with 7.5 µg pMX-IRES-GFP together with 2.5 µg pMDg and 5 µg
pMDg/p. The virus-containing supernatant of the HEK293T cells was harvested 48 h and 72 h after
transfection, supplemented with 5% FBS and 6 µg/mL Polybrene (Sigma Aldrich) and centrifuged to
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remove cell debris. Host cells were seeded at 100,000 cells per 6-well and transduced with freshly made
viral supernatant during two subsequent days. Three days after the last transduction, the host cells
were either harvested or treated further with TGFβ1. To obtain stable inducible RetroX-TET-ON double
transfectants, low passage number of skin fibroblasts or MDA-MB-231 cells were transduced following
the same procedures as for pMX-IRES-GFP: although this time with 2.5 µg pRetroX-TET-ON, 5 µg
pRetroX-Tight-Puro, 2.5 µg pMDg and 5 µg pMDg/p, and an extra virus filtration step. Heterogeneous
populations of stable cells from the skin fibroblasts were obtained after selection with G418 sulfate
(InvivoGen, San Diego, CA, USA) (600 µg/mL) and puromycin (InvivoGen) (1 µg/mL) for 7 days.
In all cases to express the inducible ZF-fusion proteins in the stable cells, doxycycline (Takara Bio)
(500 ng/mL) was supplemented to the culture medium for a total of 2 days, after which cells where
harvested or sub-cultured, where MDA-MB-231 cells were split with 4–5 days interval.
The creation of the CRISPR-dCas9 expressing HEK293T stable cell lines has been described
elsewhere [52]. Briefly, lentiviral pHAGE-EF1α constructs, encoding the dCas9-EDs were co-transfected
with the second-generation packaging plasmids pCMV∆R8.91 and pCMV-VSV-G on day one into
HEK293T cells using PEI transfection reagents (Polysciences Inc, Warrington, PA, USA) to produce
lentiviral particles. The supernatant of HEH293T cells containing virus was harvested at 48 and 72 h after
transfection. Host cells (in this case also HEK293T cells) were seeded in six-well plates and transduced
on two consecutive days (day three and four) with 1.5 mL of the viral supernatant, supplemented
with 8 µg/mL polybrene (Sigma Aldrich). The transduced cells were selected on day seven in
8 µg/mL puromycin-supplemented medium for four days and subsequently cultured in 1 µg/mL
puromycin-supplemented medium.
4.5. Transient Transfection of Cells in CRISPR Experiments
Cells were transfected at 70% confluency in a six-well culture plate, using a total of 1 µg of DNA
(500 ng sgRNAs and 500 ng dCas9-ED for wildtype cells and 1 µg sgRNAs for cells stably engineered
to constitutively express the dCas fusion protein) using PEI in a 4:1 ratio. Forty-eight hours after
transfection, 75% of the cells were harvested to assess their short-term effect on gene expression,
and 25% were subcultured to assess long-term effects at 12 days. All transient transfection experiments
were performed as biological triplicates.
4.6. DNA Methylation Analysis
Genomic DNA was isolated with phenol/chloroform extraction, treated with RNase and Proteinase
K, and bisulfite converted (EZ DNA Methylation Gold kit; Zymo Research, Irvine, CA, USA).
For bisulfite sequencing of PLOD2 fragments, bisulfite converted DNA was amplified by PCR
(Supplementary Table S1), ligated into a pCR2.1 TOPO vector with TA overhangs (Thermo
Fisher Scientific) and transformed into TOP10 competent cells. Individual colonies were selected
based on blue/white screening and the resulting plasmids were Sanger sequenced (BaseClear B.V.,
Leiden, The Netherlands) with a standard forward M13 sequencing primer. For pyrosequencing,
bisulfite converted DNA was amplified by PCR using primers for two different PLOD2 regions
(Supplementary Table S1). Biotinylated PCR products were generated according to the PyroMark
PCR kit manual (Qiagen, Venlo, the Netherlands). The samples were mixed with sequencing primers
(Supplementary Table S1) and handled further according to the PyroMark Q24 (Qiagen) instructions.
Quantitative DNA methylation levels were determined with the PyroMark software (Qiagen).
4.7. RNA Isolation and Quantitative RT-PCR
Total RNA was isolated (RNeasy Plus mini kit; Qiagen) or with TRIzol reagent (Thermo Fisher
Scientific), quantified (NanoDrop; Thermo Fisher Scientific) and reverse transcribed into cDNA using
random hexamer primers (RevertAid; Thermo Fisher Scientific). A mix of 10ng cDNA, primers (300 nM)
(Supplementary Table S1) and SYBR® Green (Roche, Basel, Switzerland) was used for quantitative
PCR analysis (ViiA7 platform and software; Thermo Fisher Scientific). Gene expression values of
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biological triplicates were either normalized to GAPDH or YWHAZ values using the standard ∆∆Ct
method. Fold expression levels were calculated from three independent experimental replicates.
4.8. Chromatin Immunoprecipitation
The chIP on fibroblasts and MDA-MB-231 cells was performed as described in [26], with ChIP-grade
antibodies listed in Supplementary Table S2. Recovered ChIP DNA fragments were quantified with
quantitative real-time PCR on the ViiA7 platform with primers (300nM) and probe (200nM) targeting
genomic regions of PLOD2 (Supplementary Table S1). The resulting qChIP data was calculated
and represented as percent of input.
4.9. Western Blotting and Immunocytochemistry
Proteins extracted from cells with RIPA buffer (Thermo Fisher Scientific), were fractionated by
SDS-PAGE and transferred to nitrocellulose membranes. The membranes were blocked in TBS-T
containing 5% skimmed milk powder, and incubated for 2 h at room temperature with primary
antibodies against PLOD2 (R&D Systems, Minneapolis, MN, USA) or HA-tag (Abcam, Cambridge, UK).
YWHAZ (Abcam) served as a loading control. Afterwards, the blots were incubated with secondary
antibodies (goat-anti-rabbit-HRP or rabbit-anti-mouse-HRP (DAKO, Glostrup, Denmark)) for 1 h
at room temperature, and chemi-luminescence was detected with ECL (Thermo Fisher Scientific).
For immunocytochemistry, cells cultured in 24 wells plates or chamber slides (Thermo Fisher
Scientific) were fixed with acetone/methanol (1:1 ratio) for 10 min at −20 ◦C. The cells were rehydrated
with PBS for 10 min and blocked in 10% donkey serum (Abcam). Antibodies against PLOD2 (Sigma
Aldrich) or Ki67 (Abcam) were incubated on fixed chamber slides for 1 h at room temperature.
After washing with PBS, the slides were incubated for 30 min at room temperature with donkey
anti-mouse A555-Cy3 (Thermo Fisher Scientific) (for PLOD2) or donkey anti-mouse A488-FITC (Thermo
Fisher Scientific), (for Ki67) in DAPI (Thermo Fisher Scientific), with 2% BSA. Afterward, the slides
were washed, mounted in Citi Fluor (EMS, Hatfield, PA, USA) and analyzed with the TissueFAXS
(TissueGnostics, Vienna, Austria) fluorescence imaging system. For quantitation of positive cells,
total areas of the wells were scanned and intensities were adjusted to the corresponding serotype
control and calculated per nuclei (by DAPI; Thermo Fisher Scientific) with TissueQuest software
(TissueGnostics).
4.10. Statistics
Statistical tests were performed using Graphpad Prism 7 software (GraphPad, San Diego, CA, USA).
Comparison between target conditions, and controls were investigated with an unpaired two-tailed
Student’s t-test or one-way ANOVA, depending on the number of conditions. Differences were
considered statistically significant when the p-value was * p < 0.05, ** p < 0.01, *** p < 0.001. All data are
presented as the mean ±SEM of three biological replicates, unless stated differently. Pyrosequencing
data were analyzed using a two-way ANOVA.
5. Conclusions
In conclusion, our study provides an example of effective gene repression by KRAB-induced
heterochromatin without targeted DNA methylation, which is resilient to continuous TGFβ1
transcriptional activation. This strategy of targeting PLOD2 can be used to further develop epigenetic
targeting approaches to prevent f.e. tissue fibrosis. As fibrosis still represents an unmet medical need,
our approach together with the clinical progress of delivering gene-editing tools [3], might open a novel
avenue towards personalized treatment options.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/10/
3634/s1.
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KRAB Krüppel-associated box
SKD Super KRAB Domain
dCas9 Deactivated Cas9
sgRNA Single guide RNA
PLOD2 Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase 2
ZF Zinc finger
LH2 Lysyl hydroxylase 2
KAP-1 KRAB-associated protein 1
HP1 Heterochromatin Protein 1
CRISPR Clustered regularly interspaced short palindromic repeats
M.SssI CpG Methyltransferase
HEK293T Human embryonic kidney cells
TALEN Transcription activator-like effectors
ED Effector domain
TGFβ1 Transforming growth factor beta-1
TSS Transcription start site
HDFs Human dermal fibroblasts
mRNA Messenger RNA
DNA Deoxyribonucleic acid
RNA Ribonucleic acid
NoED No effector domain
EV Empty vector
CpGi CG island
MTase Methyltransferase
Dnmt DNA methyltransferase
iPSCs Induced pluripotent stem cells
FBS Fetal bovine serum
DMEM Dulbecco’s Modified Eagle Medium
BSA Bovine serum albumin
PCR Polymerase chain reaction
cDNA complementary DNA
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
YWHAZ 14-3-3 protein zeta/delta (14-3-3ζ)
ChIP Chromatin immunoprecipitation
RIPA Radioimmunoprecipitation assay
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
TBS-T Tris-buffered saline and Tween 20
PBS Phosphate-Buffered Saline
DAPI 4′,6-diamidino-2-phenylindole
ANOVA Analysis of variance
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